In bio-tech world - there is no guaranteed home-runs.
The LLY news has opened a big door for AVXL as the focus will changed to alternative approaches and which drug is ahead of everyone.
A2-73 is proven that it is safe, non-toxic and crosses Brain-Blood-Barrier (BBB) and based on recent PR shows that it slowed the decline at 41 weeks - which is big as 41 weeks is long time
People will be skeptical as the sample size is very small.
However if A2-73 is the last man standing - even if not very effective may still be a winner (and may make money for us as investors)
Is someone buying any aging DH for a playoff run or Does AVXL produce both the new avenue and the affordable contract for the step up from AAA to the SHOW?
News 
Market Data 
Discover 
